A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
Authors:
- Julien DumurgierJDJulien Dumurgier
- Séverine SabiaSSSéverine Sabia
- Henrik ZetterbergHZHenrik Zetterberg
- Charlotte E. TeunissenCTCharlotte E. Teunissen
- Bernard HanseeuwBHBernard Hanseeuw
- Adelina OrellanaAOAdelina Orellana
- Susanna SchraenSSSusanna Schraen
- Audrey GabelleAGAudrey Gabelle
- Mercè BoadaMBMercè Boada
- Thibaud LebouvierTLThibaud Lebouvier
- Eline A.J. WillemseEWEline A.J. Willemse
- Emmanuel CognatECEmmanuel Cognat
Open Access
- 2 June 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (7) , e669-e678
Abstract
Background and Objectives To elaborate a new algorithm to establish a standardized method to define cutoffs for CSF biomarkers of Alzheimer disease (AD) by validating the algorithm against CSF classification derived from PET imaging. Methods Low and high levels of CSF phosphorylated tau were first identified to establish optimal cutoffs for CSF β-amyloid (Aβ) peptide biomarkers. These Aβ cutoffs were then used to determine cutoffs for CSF tau and phosphorylated tau markers. We compared this algorithm to a reference method, based on tau and amyloid PET imaging status (ADNI study), and then applied the algorithm to 10 large clinical cohorts of patients. Results A total of 6,922 patients with CSF biomarker data were included (mean [SD] age: 70.6 [8.5] years, 51.0% women). In the ADNI study population (n = 497), the agreement between classification based on our algorithm and the one based on amyloid/tau PET imaging was high, with Cohen9s kappa coefficient between 0.87 and 0.99. Applying the algorithm to 10 large cohorts of patients (n = 6,425), the proportion of persons with AD ranged from 25.9% to 43.5%. Discussion The proposed novel, pragmatic method to determine CSF biomarker cutoffs for AD does not require assessment of other biomarkers or assumptions concerning the clinical diagnosis of patients. Use of this standardized algorithm is likely to reduce heterogeneity in AD classification.Keywords
This publication has 47 references indexed in Scilit:
- Use of amyloid-PET to determine cutpoints for CSF markersNeurology, 2016
- Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014Alzheimer's & Dementia, 2015
- Benchmarking biomarker‐based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDemAlzheimer's & Dementia, 2015
- Impact of cerebro-spinal fluid biomarkers of Alzheimer’s disease in clinical practice: a multicentric studyJournal of Neurology, 2013
- Determining Cut-Points for Alzheimer’s Disease Biomarkers: Statistical Issues, Methods and ChallengesBiomarkers in Medicine, 2012
- CSF biomarkers cutoffs: the importance of coincident neuropathological diseasesActa Neuropathologica, 2012
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010Journal of Neuropathology & Experimental Neurology, 2012
- Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal SubjectsJournal of Nuclear Medicine, 2012
- Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer DiseaseArchives of General Psychiatry, 2004
- Using the Kappa Coefficient as a Measure of Reliability or ReproducibilityChest, 1998